Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-3 HCV Infected Russian and Swedish Population: Results from a Phase 3, Prospective Trial

被引：0

作者：

Weiland, Ola ^{[1
]}

Zhdanov, Konstantin ^{[2
]}

Chulanov, Vladimir P. ^{[3
]}

McNabb, Brian L. ^{[4
]}

Lu, Sophia ^{[5
]}

Svarovskaia, Evguenia S. ^{[6
]}

McNally, John ^{[4
]}

Brainard, Diana M. ^{[4
]}

Subramanian, Mani ^{[4
]}

Abdurakhmanov, Dzhamal ^{[7
]}

Isakov, Vasily ^{[8
]}

机构：

[1] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Infect Dis, Dept Med, Stockholm, Sweden

[2] Mil Med Acad, Dept Infect Dis, St Petersburg, Russia

[3] Cent Res Inst Epidemiol, Clin Diagnost & Res Ctr, Moscow, Russia

[4] Gilead Sci Inc, Clin Res, 353 Lakeside Dr, Foster City, CA 94404 USA

[5] Gilead Sci Inc, Biostat, 353 Lakeside Dr, Foster City, CA 94404 USA

[6] Gilead Sci Inc, Virol, 353 Lakeside Dr, Foster City, CA 94404 USA

[7] Sechenov First Moscow State Univ, Moscow, Russia

[8] Fed Res Ctr Nutr Biotechnol & Food Safety, Dept Gastroenterol & Hepatol, Moscow, Russia

来源：

HEPATOLOGY | 2017年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1186

引用

页码：639A / 639A

页数：1

共 50 条

[1] Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population: Results from a Phase 3, Clinical Trial
Wei, Lai
Xie, Qing
Hou, Jinlin
Tang, Hong
Ning, Qin
Cheng, Jun
Nan, Yuemin
Zhang, Lunli
Li, Jun
Jiang, Jianning
McNabb, Brian L.
Zhang, Fangqiu
Camus, Gregory
Mo, Hongmei
McNally, John
Brainard, Diana M.
Subramanian, Mani
Gong, Guozhong
Mou, Zhuangbo
Wu, Shanming
Wang, Qui-Qiang
Hu, Peng
Gao, Yanhang
Jia, Jidong
Duan, Zhongping
HEPATOLOGY, 2017, 66 : 642A - 642A
[2] Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial
Wei, Lai
Xie, Qing
Huang, Yan
Wu, Shanming
Xu, Min
Tang, Hong
Cheng, Jun
Gao, Yanhang
Mou, Zhuangbo
Dou, Xiaoguang
Nan, Yuemin
Ning, Qin
Mao, Yimin
Stamm, Luisa
Lu, Sophia
Dvory-Sobol, Hadas
Mo, Hongmei
Brainard, Diana
Yang, Yongfeng
Wang, Guiqiang
Hu, Peng
Zhang, Lunli
Gao, Zhiliang
Lin, Feng
Shang, Jia
Gong, Guozhong
Li, Jun
Su, Minghua
Duan, Zhongping
Hou, Jinlin
Jia, Jidong
HEPATOLOGY, 2018, 68 : 379A - 379A
[3] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR IN A GENOTYPE 1-6 HCV INFECTED POPULATION FROM SINGAPORE, MALAYSIA, THAILAND, AND VIETNAM: RESULTS FROM A PHASE 3, CLINICAL TRIAL
Lim, Seng Gee
Mohamed, Rosmawati
Phuong Le
Tee, Hoi Poh
McNabb, Brian
Lu, Sofia
Lu, Julia
McNally, John
Brainard, Diana M.
Subramanian, G. Mani
Yip, Christina Sze Man
Huang, Hai Cheng
Tan, Chee Kiat
Tanwandee, Tawesak
Kinh Nguyen Van
Piratvisuth, Teerha
GUT, 2018, 67 : A100 - A100
[4] Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-6 HCV Infected Population from Singapore, Malaysia, Thailand, and Vietnam: Results from a Phase 3, Clinical Trial
Lim, Seng Gee
Mohamed, Rosmawati
Le, Phuong
Tee, Hoi Poh
McNabb, Brian L.
Lu, Sophia
Lu, Julia
McNally, John
Brainard, Diana M.
Subramanian, Mani
Tan, Chee-Kiat
Tanwandee, Tawesak
Kinh Nguyen Van
Piratvisuth, Teerha
HEPATOLOGY, 2017, 66 : 586A - 586A
[5] Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
Ferret, M. B.
Pineda, J.
Panero, J. L. C.
Rodriguez, M.
Morillas, R. M.
Pascasio, J. M.
Rivero, A.
Mcnabb, B.
Zhang, G.
Camus, G.
Stamm, L.
Brainard, D.
Subramanian, M.
Carrion, J. A.
Andrade, R. J.
Amado, L. E. M.
Turnes, J.
Lens, S.
Casado, M.
Esteban, R.
JOURNAL OF HEPATOLOGY, 2018, 68 : S20 - S21
[6] EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN GENOTYPE 3 AND 6 HCV PATIENTS IN EAST CHINA
Wang Donghui
Jiang, Suwen
Liu, Linsong
Fan, Lingyan
Hu, Airong
HEPATOLOGY, 2021, 74 : 589A - 590A
[7] Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
Mushtaq, Saima
Akhter, Tayyab Saeed
Khan, Amjad
Sohail, Aamir
Khan, Arshad
Manzoor, Sobia
FRONTIERS IN PHARMACOLOGY, 2020, 11
[8] Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
Tetsuo Takehara
Naoya Sakamoto
Shuhei Nishiguchi
Fusao Ikeda
Tomohide Tatsumi
Yoshiyuki Ueno
Hiroshi Yatsuhashi
Yasuhiro Takikawa
Tatsuo Kanda
Minoru Sakamoto
Akihiro Tamori
Eiji Mita
Kazuaki Chayama
Gulan Zhang
Shampa De-Oertel
Hadas Dvory-Sobol
Takuma Matsuda
Luisa M. Stamm
Diana M. Brainard
Yasuhito Tanaka
Masayuki Kurosaki
Journal of Gastroenterology, 2019, 54 : 87 - 95
[9] A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study
Foster, Graham R.
Thompson, Alex J.
Ruane, Peter J.
Borgia, Sergio M.
Dore, Gregory
Workowski, Kimberly
Hyland, Robert H.
Wang, Jing
Svarovskaia, Evguenia S.
Stamm, Luisa M.
Brainard, Diana M.
Subramanian, Mani
McHutchison, John G.
Berg, Thomas
Agarwal, Kosh
Conway, Brian
Feld, Jordan J.
Willems, Bernard E.
Roberts, Stuart K.
HEPATOLOGY, 2016, 64 : 135A - 136A
[10] Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
Takehara, Tetsuo
Sakamoto, Naoya
Nishiguchi, Shuhei
Ikeda, Fusao
Tatsumi, Tomohide
Ueno, Yoshiyuki
Yatsuhashi, Hiroshi
Takikawa, Yasuhiro
Kanda, Tatsuo
Sakamoto, Minoru
Tamori, Akihiro
Mita, Eiji
Chayama, Kazuaki
Zhang, Gulan
De-Oertel, Shampa
Dvory-Sobol, Hadas
Matsuda, Takuma
Stamm, Luisa M.
Brainard, Diana M.
Tanaka, Yasuhito
Kurosaki, Masayuki
JOURNAL OF GASTROENTEROLOGY, 2019, 54 (01) : 87 - 95

← 1 2 3 4 5 →